Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators.

Théroux P, Chaitman BR, Danchin N, Erhardt L, Meinertz T, Schroeder JS, Tognoni G, White HD, Willerson JT, Jessel A.

Circulation. 2000 Dec 19;102(25):3032-8.

2.

Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study.

Boyce SW, Bartels C, Bolli R, Chaitman B, Chen JC, Chi E, Jessel A, Kereiakes D, Knight J, Thulin L, Theroux P; GUARD During Ischemia Against Necrosis (GUARDIAN) Study Investigators.

J Thorac Cardiovasc Surg. 2003 Aug;126(2):420-7.

3.
4.

Cardioprotective effects of the Na(+)/H(+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA.

Rupprecht HJ, vom Dahl J, Terres W, Seyfarth KM, Richardt G, Schultheibeta HP, Buerke M, Sheehan FH, Drexler H.

Circulation. 2000 Jun 27;101(25):2902-8.

5.

Prognostic significance of elevated creatine kinase MB after coronary bypass surgery and after an acute coronary syndrome: results from the GUARDIAN trial.

Gavard JA, Chaitman BR, Sakai S, Stocke K, Danchin N, Erhardt L, Gallo R, Chi E, Jessel A, Théroux P; GUARd During Ischemia Against Necrosis (GUARDIAN) Investigators.

J Thorac Cardiovasc Surg. 2003 Sep;126(3):807-13.

6.

GUARD During Ischemia Against Necrosis (GUARDIAN) trial in acute coronary syndromes.

Erhardt LR.

Am J Cardiol. 1999 May 20;83(10A):23G-25G.

PMID:
10482177
7.
8.

Cariporide Aventis.

Chin B, Lip GY.

Curr Opin Investig Drugs. 2000 Nov;1(3):340-6. Review.

PMID:
11249717
9.

Dose-dependent reduction of myocardial infarct mass in rabbits by the NHE-1 inhibitor cariporide (HOE 642).

Linz W, Albus U, Crause P, Jung W, Weichert A, Schölkens BA, Scholz W.

Clin Exp Hypertens. 1998 Oct;20(7):733-49.

PMID:
9764718
10.

Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery.

Weber W, Harnisch L, Jessel A; GUARDIAN trial investigators.

Clin Pharmacol Ther. 2002 Jun;71(6):457-67.

PMID:
12087349
11.

Pharmacology and clinical assessment of cariporide for the treatment coronary artery diseases.

Karmazyn M.

Expert Opin Investig Drugs. 2000 May;9(5):1099-108. Review.

PMID:
11060730
13.

The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial.

Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, Linssen G, Tebbe U, Schröder R, Tiemann R, Machnig T, Neuhaus KL; ESCAMI Investigators.

J Am Coll Cardiol. 2001 Nov 15;38(6):1644-50.

14.

Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study.

Mentzer RM Jr, Bartels C, Bolli R, Boyce S, Buckberg GD, Chaitman B, Haverich A, Knight J, Menasché P, Myers ML, Nicolau J, Simoons M, Thulin L, Weisel RD; EXPEDITION Study Investigators.

Ann Thorac Surg. 2008 Apr;85(4):1261-70. doi: 10.1016/j.athoracsur.2007.10.054.

PMID:
18355507
15.

Cardioprotection with cariporide, a sodium-proton exchanger inhibitor, after prolonged ischemia and reperfusion in senescent rats.

Besse S, Tanguy S, Boucher F, Le Page C, Rozenberg S, Riou B, Leiris Jd, Swynghedauw B.

Exp Gerontol. 2004 Sep;39(9):1307-14.

PMID:
15489053
16.

Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients.

Testa L, Van Gaal WJ, Bhindi R, Biondi-Zoccai GG, Abbate A, Agostoni P, Porto I, Andreotti F, Crea F, Banning AP.

J Thorac Cardiovasc Surg. 2008 Oct;136(4):884-93. doi: 10.1016/j.jtcvs.2007.12.062. Epub 2008 Jun 18. Review.

17.
19.

The preischemic combination of the sodium-hydrogen exchanger inhibitor cariporide and the adenosine agonist AMP579 acts additively to reduce porcine myocardial infarct size.

Kristo G, Yoshimura Y, Ferraris SP, Jahania SA, Mentzer RM Jr, Lasley RD.

J Am Coll Surg. 2004 Oct;199(4):586-94.

PMID:
15454144
20.

Sodium-hydrogen exchange inhibition and beta-blockade additively decrease infarct size.

Wang P, Zaragoza C, Holman W.

Ann Thorac Surg. 2007 Mar;83(3):1121-7.

PMID:
17307470

Supplemental Content

Support Center